Search Results
266 results
Your search is now limited to «Gilead» expert search.
WN.com 01/20/2019 05:32
PhRMA Welcomes Genentech and Gilead Sciences to Association WASHINGTON, Jan. Pharmaceutical Research and Manufacturers of America (PhRMA) ......
More from WN.com:
FiercePharmaManufacturing 01/18/2019 04:57
Gilead loses its vice president of clinical research to NASH-focused Terns; Spectrum unloads its marketed portfolio to India's Aurobindo in a deal worth $300 million; Aslan's lead drug varlitinib misses the mark in a gastric cancer trial; and more.
More from FiercePharmaManufacturing:
NASDAQ 01/17/2019 17:29
Gilead was off 48% from its all-time high in July 2015, while Celgene was down 56% from its high-water mark set in September 2017.
More from NASDAQ:
Xconomy 01/17/2019 16:56
Quirk most recently worked at Gilead Sciences (NASDAQ: GILD), where she was vice president, clinical research.
More from Xconomy:
PR Newswire 01/17/2019 10:48
With the addition of Genentech and Gilead, PhRMA now represents all of the top 20 biopharmaceutical companies.
More from PR Newswire:
FierceMedicalDevices 01/17/2019 09:20
Gilead’s vice president of clinical research, Erin Quirk, is joining the NASH and cancer-focused Terns Pharmaceuticals as its new chief medical officer.
More from FierceMedicalDevices:
Zacks.com 01/17/2019 08:48
Gilead ( GILD - Free Report) is yielding 3.4% while AbbVie ( ABBV - Free Report) is at 4.9.
More from Zacks.com:
Seeking Alpha 01/14/2019 12:01
Gilead’s financial statements are published here, and you can click here to view the spreadsheet in a new window.
More from Seeking Alpha:
Business Insider 01/10/2019 13:40
Amgen to Gilead have billions in cash, and execs are hinting about M&A.
More from Business Insider:
PharmaBiz.com 01/09/2019 02:36
Gilead’s Epclusa receives Japanese approval for chronic HCV infection with decompensated cirrhosis.
More from PharmaBiz.com:
Gilead Sciences has signed a licensing and collaboration agreement, potentially worth $785m, with South Korea-based Yuhan to develop new therapeutic candidates for the treatment of advanced fibrosis due to nonalcoholic steatohepatitis (NASH.
More from Pharmaceutical Business Review:
Business Wire 01/08/2019 01:00
All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
More from Business Wire:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications